GRI Bio, Inc. (GRI)
| Market Cap | 1.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.26M |
| Shares Out | 2.93M |
| EPS (ttm) | -7.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 265,708 |
| Open | 0.700 |
| Previous Close | 0.685 |
| Day's Range | 0.622 - 0.710 |
| 52-Week Range | 0.302 - 106.290 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 12.00 (+1,777.93%) |
| Earnings Date | Nov 14, 2024 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GRI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of ...
GRI Bio Announces Exercise of Warrants
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modula...
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
Live video webcast on Wednesday, October 2 nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology co...
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modul...
GRI Bio to Present at the 2024 European Respiratory Congress
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modul...
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and toplin...
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
Live video webcast on Wednesday, July 17 th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology compa...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio Regains Compliance with Nasdaq
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modula...
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice
GRI Bio to Present at the 8th Annual IPF Summit
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Closing of $4.0 Million Public Offering
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Comp...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14 th International Congress on Autoimmunity
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Data presented at the 14 th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projecte...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score ...
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21 st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancin...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modul...
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innova...
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation